Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

by Moriarty, Patrick M., MD   Thompson, Paul D., MD   Cannon, Christopher P., MD   Guyton, John R., MD   Bergeron, Jean, MD   Zieve, Franklin J., MD, PhD   Bruckert, Eric, MD   Jacobson, Terry A., MD   Kopecky, Stephen L., MD   Baccara-Dinet, Marie T., MD   Du, Yunling, PhD   Pordy, Robert, MD   Gipe, Daniel A., MD Published in Journal of clinical lipidology (2015)

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

by Moriarty, Patrick M., MD   Jacobson, Terry A., MD   Bruckert, Eric, MD   Thompson, Paul D., MD   Guyton, John R., MD   Baccara-Dinet, Marie T., MD   Gipe, Daniel, MD Published in Journal of clinical lipidology (2014)

An assessment by the Statin Intolerance Panel: 2014 update

by Guyton, John R., MD, FNLA   Bays, Harold E., MD, FNLA   Grundy, Scott M., MD, PhD, FNLA   Jacobson, Terry A., MD, FACP, FNLA Published in Journal of clinical lipidology (2014)

ALIROCUMAB TREATMENT IN A REAL WORLD SETTING: SAFETY UPDATE FROM AN OPEN-LABEL TREATMENT EXTENSION TO THE ODYSSEY PROGRAM FOR PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEM...

by Guyton, John R   Hovingh, G. Kees   Langslet, Gisle   Dufour, Robert   Baccara-Dinet, Marie   Din-Bell, Chantal   Manvelian, Garen   Farnier, Michel Published in Journal of the American College of Cardiology (2017)

What Works, What Doesn’t? Three Studies Designed to Improve Survey Response

by Sun, Hanyu   Newsome, Jocelyn   McNulty, Jennifer   Levin, Kerry   Langetieg, Pat   Schafer, Brenda   Guyton, John Published in Field methods (01.08.2020)

ON-TREATMENT LDL-C LEVELS WHEN ALIROCUMAB DOSE IS DECREASED FROM 150 TO 75 MG EVERY 2 WEEKS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM ODYSSEY OLE

by Farnier, Michel   Guyton, John   Langslet, Gisle   Dufour, Robert   Baccara-Dinet, Marie   Din-Bell, Chantal   Manvelian, Garen   Hovingh, G. Kees Published in Journal of the American College of Cardiology (2017)

Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia

by Maki, Kevin C., PhD, FNLA   Guyton, John R., MD, FNLA   Orringer, Carl E., MD, FNLA   Hamilton-Craig, Ian, MBBS, PhD   Alexander, Dominik D., PhD, MSPH   Davidson, Michael H., MD, FNLA Published in Journal of clinical lipidology (2016)

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher

by Ginsberg, Henry N   Rader, Daniel J   Raal, Frederick J   Guyton, John R   Baccara-Dinet, Marie T   Lorenzato, Christelle   Pordy, Robert   Stroes, Erik Published in Cardiovascular drugs and therapy (2016)

EFFICACY AND SAFETY OF DIFFERENT DOSING REGIMENS OF ALIROCUMAB (STARTING DOSES OF 75 MG EVERY TWO WEEKS AND 150 MG EVERY FOUR WEEKS) VERSUS PLACEBO IN PATIENTS WITH HYPERCHOLESTERO...

by Stroes, Erik S.G   Guyton, John   Farnier, Michel   Lepor, Norman   Civeira, Fernando   Gaudet, Daniel   Watts, Gerald   Manvelian, Garen   Lecorps, Guillaume   Baccara-Dinet, Marie Published in Journal of the American College of Cardiology (17.03.2015)

Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis

by Connelly, Margery A   Velez Rivera, Jonathan   Guyton, John R   Siddiqui, Mohammad Shadab   Sanyal, Arun J Published in Alimentary pharmacology & therapeutics (01.08.2020)